Metabolic Drug-Drug Interactions: Perspective from FDA Medical and Clinical Pharmacology Reviewers
- 1 January 1997
- book chapter
- Published by Elsevier
- Vol. 43, 231-238
- https://doi.org/10.1016/s1054-3589(08)60208-2
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Inhibition of Alprazolam and Desipramine Hydroxylation In Vitro by Paroxetine and FluvoxamineJournal of Clinical Psychopharmacology, 1995
- Inhibitors of alprazolam metabolism in vitro: effect of serotonin- reuptake-inhibitor antidepressants, ketoconazole and quinidine.Published by Wiley ,1994
- Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazoleClinical Pharmacology & Therapeutics, 1994
- Utility of in vitro drug metabolism data in predicting in vivo metabolic clearanceBiochemical Pharmacology, 1994
- Terfenadine-Ketoconazole InteractionJAMA, 1993
- A potentially hazardous interaction between erythromycin and midazolamClinical Pharmacology & Therapeutics, 1993
- Fluoxetine impairs clearance of alprazolam but not of clonazepamClinical Pharmacology & Therapeutics, 1992
- In vitro forecasting of drugs which may interfere with the biotransformation of midazolamEuropean Journal of Clinical Pharmacology, 1991
- Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.British Journal of Clinical Pharmacology, 1990